drugset / Trial / NCT07252908
A Phase II Clinical Trial on the Efficacy and Safety of TQC3721 Inhalation Powder
RandomizedParallel-groupQuadruple-blindTreatment
Summary
To evaluate the efficacy and safety of TQC3721 inhalation powder in patients with moderate to severe Chronic obstructive pulmonary disease (COPD).
Timeline
- Start
- 2025-12-22
- Primary completion
- 2026-04-28
- Completion
- 2026-05-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TQC3721 | Unknown | 750 ug | Other |
| Subject | TQC3721 | Unknown | 1000 ug | Other |